Vaccine provides poultry producers with a much-needed tool to help minimize the impact of avian metapneumovirus 

DULUTH, GA (October 30, 2024) – Boehringer Ingelheim announced today that the U.S. Department of Agriculture (USDA) has granted a permit allowing for importation of its TUR-3 (Newcastle disease, avian paramyxovirosis type 3 and turkey rhinotracheitis, killed virus) vaccine. TUR-3, a killed vaccine currently licensed for use throughout Europe, will be available for primary vaccination of U.S. turkey and chicken flocks against avian metapneumovirus subtype B. Avian metapneumovirus can result in severe respiratory symptoms and increased mortality in poultry as well as a decrease in egg production.  

“U.S. poultry producers have been challenged by avian metapneumovirus, and it’s positive news that our TUR-3 vaccine will be available as a tool to support USDA and industry efforts to protect flocks against this highly contagious respiratory disease,” said Steve Boren, head of the Boehringer Ingelheim U.S. Livestock and Equine business. “At Boehringer Ingelheim, prevention isn't just a concept – it's the very foundation of our company. We understand that disease outbreaks not only impact poultry health, but also the livelihoods of producers and the security of our food supply. TUR-3 is a proven vaccine and a valuable tool for poultry producers. It works by protecting the health and productivity of flocks.” 

Boehringer responded to a request by the USDA Center for Veterinary Biologics (CVB) for vaccines to protect against the virus. There is no vaccine currently licensed in the U.S. to address this disease challenge.  

“By leveraging the Boehringer global supply network, we were able to respond to USDA’s call for vaccines and support poultry producers who have been impacted by the virus,” said Boren. “We are steadfast in our commitment to delivering solutions that safeguard the health of poultry, and this import permit brings us one step closer to that goal. We are eager to continue our collaboration with USDA and poultry producers across the U.S., contributing to a healthier future for all." 

TUR-3 is expected to be available in the U.S. in November. It is permitted for use domestically in turkeys and chickens. Customers should contact their local Boehringer representative for additional product information. 

About Boehringer Ingelheim Animal Health 

Boehringer Ingelheim provides innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society. Learn more at bi-animalhealth.com.  

About Boehringer Ingelheim 

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Lean more at boehringer-ingelheim.com/us. 

Media Contact
Elizabeth Breeding
Boehringer Ingelheim
Associate Director, PR and Communications
elizabeth.breeding@boehringer-ingelheim.com